» Articles » PMID: 28361029

Risk Factors of Osteonecrosis of the Jaw After Tooth Extraction in Osteoporotic Patients on Oral Bisphosphonates

Overview
Specialty Radiology
Date 2017 Apr 1
PMID 28361029
Citations 23
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: The aim of this study was to investigate the incidence of bisphosphonate-related osteonecrosis of the jaw (BRONJ) after tooth extraction in patients with osteoporosis on oral bisphosphonates in Korea and to evaluate local factors affecting the development of BRONJ.

Materials And Methods: The clinical records of 320 patients who underwent dental extraction while receiving oral bisphosphonates were reviewed. All patients had a healing period of more than 6 months following the extractions. Each patient's clinical record was used to assess the incidence of BRONJ; if BRONJ occurred, a further radiographic investigation was carried out to obtain a more definitive diagnosis. Various local factors including age, gender, extraction site, drug type, duration of administration, and C-terminal telopeptide (CTx) level were retrieved from the patients' clinical records for evaluating their effect on the incidence of BRONJ.

Results: Among the 320 osteoporotic patients who underwent tooth extraction, 11 developed BRONJ, reflecting an incidence rate of 3.44%. Out of the local factors that may affect the incidence of BRONJ, gender, drug type, and CTx level showed no statistically significant effects, while statistically significant associations were found for age, extraction site, and duration of administration. The incidence of BRONJ increased with age, was greater in the mandible than the maxilla, and was associated with a duration of administration of more than 3 years.

Conclusion: Tooth extraction in patients on oral bisphosphonates requires careful consideration of their age, the extraction site, and the duration of administration, and close postoperative follow-up should be carried out to facilitate effective early management.

Citing Articles

High-dose denosumab (Xgeva®) Associated Medication-Related Osteonecrosis of the Jaws (MRONJ): incidence and clinical characteristics in a retrospective analysis of 1278 patients.

Moon C, Kim H, Park J, Park W, Kim H, Jung Y Support Care Cancer. 2024; 32(12):774.

PMID: 39499349 DOI: 10.1007/s00520-024-08974-6.


Potential role of comprehensive dental care in preventing medication related osteonecrosis of the jaw (MRONJ): a single centre study.

Alblazi K, Nabil S, Tumian N, Yunus S, Ramli R BMC Oral Health. 2024; 24(1):1291.

PMID: 39455955 PMC: 11512473. DOI: 10.1186/s12903-024-05081-0.


Key insights into antiresorptive drug use and osteonecrosis in osteoporotic patients undergoing tooth extractions: A clinical and CBCT assessment.

Moreno-Rabie C, Fontenele R, Oliveira-Santos N, Nogueira-Reis F, Van den Wyngaert T, Jacobs R Osteoporos Int. 2024; 35(8):1431-1440.

PMID: 38767743 PMC: 11282135. DOI: 10.1007/s00198-024-07108-2.


Prevalence and Factors Influencing Post-Operative Complications following Tooth Extraction: A Narrative Review.

Dignam P, Elshafey M, Jeganathan A, Foo M, Park J, Ratnaweera M Int J Dent. 2024; 2024:7712829.

PMID: 38756385 PMC: 11098612. DOI: 10.1155/2024/7712829.


Medication-related osteonecrosis of the jaw: Case series and literature review.

Kimathi D, Butt F, Guthua S, Waweru W Clin Case Rep. 2024; 12(4):e8788.

PMID: 38645603 PMC: 11031743. DOI: 10.1002/ccr3.8788.


References
1.
Mavrokokki T, Cheng A, Stein B, Goss A . Nature and frequency of bisphosphonate-associated osteonecrosis of the jaws in Australia. J Oral Maxillofac Surg. 2007; 65(3):415-23. DOI: 10.1016/j.joms.2006.10.061. View

2.
Taylor T, Bryant C, Popat S . A study of 225 patients on bisphosphonates presenting to the bisphosphonate clinic at King's College Hospital. Br Dent J. 2013; 214(7):E18. DOI: 10.1038/sj.bdj.2013.327. View

3.
Saia G, Blandamura S, Bettini G, Tronchet A, Totola A, Bedogni G . Occurrence of bisphosphonate-related osteonecrosis of the jaw after surgical tooth extraction. J Oral Maxillofac Surg. 2010; 68(4):797-804. DOI: 10.1016/j.joms.2009.10.026. View

4.
Khosla S, Burr D, Cauley J, Dempster D, Ebeling P, Felsenberg D . Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res. 2007; 22(10):1479-91. DOI: 10.1359/jbmr.0707onj. View

5.
Stepensky D, Kleinberg L, Hoffman A . Bone as an effect compartment : models for uptake and release of drugs. Clin Pharmacokinet. 2003; 42(10):863-81. DOI: 10.2165/00003088-200342100-00001. View